Literature DB >> 26991939

2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.

Lena Shukla1, Laura A Ajram2, Malcolm Begg2, Brian Evans1, Rebecca H Graves3, Simon T Hodgson1, Sean M Lynn4, Afjal H Miah1, Jonathan M Percy5, Panayiotis A Procopiou6, Stephen A Richards4, Robert J Slack2.   

Abstract

A number of potent 2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine CCR4 antagonists binding to the extracellular allosteric site were synthesised. (R)-N-(2,4-Dichlorobenzyl)-2-(2-(pyrrolidin-2-ylmethyl)-2,8-diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine (R)-(18a) has high affinity in both the [(125)I]-TARC binding assay with a pKi of 8.8, and the [(35)S]-GTPγS functional assay with a pIC50 of 8.1, and high activity in the human whole blood actin polymerisation assay (pA2 = 6.7). The most potent antagonists were also investigated for their ability to induce endocytosis of CCR4 and were found to internalise about 60% of the cell surface receptors, a property which is not commonly shared by small molecule antagonists of chemokine receptors.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CCR4 antagonist; Endocytosis; Receptor internalisation

Mesh:

Substances:

Year:  2016        PMID: 26991939     DOI: 10.1016/j.ejmech.2016.02.058

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.

Authors:  Tyler C Beck; Kyle R Beck; Calvin B Holloway; Richard A Hemings; Thomas A Dix; Russell A Norris
Journal:  Front Pharmacol       Date:  2020-08-28       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.